Response to Letter “Perioperative Implications of Belzutifan Therapy in HIF2A-Related Pheochromocytoma and Paraganglioma”

Hussam R Alkaissi^a, Karel Pacák^{b c d e}

1. ^aDepartment of Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD. Electronic address: hussam.alkaissi@nih.gov
2. ^bDepartment of Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, MD
3. ^cCenter of Adrenal Endocrine Tumors, AKESO, Prague 5, Czech Republic
4. ^dCenter for Adrenal Diseases, Faculty of Medicine, Palacky University, Olomouc
5. ^eFaculty of Medicine, 5th Department of Medicine, Comenius University, Bratislava, Slovakia